www.thehindubusinessline.com ·
Fast Tracking Biopharma Goalswithregulatory Reform
Topic context
This topic has been covered 431912 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRegulatory reforms in EU, US, and India aim to accelerate biosimilar development, reducing time-to-market and development costs. This benefits biosimilar manufacturers like Biocon (India) by lowering R&D expenses and enabling faster product launches. The Indian government's Biopharma Shakti mission provides capital support, enhancing India's competitiveness as a manufacturing hub. The channel is regulatory: streamlined approval processes reduce compliance costs and speed up revenue generation for biosimilar producers. Impact is global but particularly strong for Indian firms due to local policy support.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- EMA reflection paper on March 16, 2023 promotes tailored clinical approach for biosimilars, potentially reducing development timelines from 5-8 years to 2-4 years.
- FDA proposed similar changes, eliminating mandatory comparative efficacy studies (CES).
- India has about 135 approved biosimilars, market valued at $1.5 billion, growing at 20% annually.
- Indian government’s ₹10,000 crore Biopharma Shakti mission aims to establish India as a global biosimilar manufacturing hub.
- CDSCO draft guidelines (May 2025) seen as insufficient due to discretionary nature and reliance on animal studies.
India may gain market share in global biosimilars; moderate export revenue growth expected.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- EM_MARKETSmid
- PHARMA_BIOTECHmid
